Preferred Label : palbociclib;

MeSH note : specific inhibitor of cyclin-dependent kinases 4 & 6; structure in first source;

CISMeF synonym : PD 0332991;

MeSH synonym : 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one;

MeSH hyponym : PD0332991; PD-0332991;

Is substance : O;

UNII : G9ZF61LE7G;

InChIKey : AHJRHEGDXFFMBM-UHFFFAOYSA-N;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3470396/fr/ibrance-palbociclib-cancer-du-sein
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
palbociclib
antineoplastic agents
protein kinase inhibitors
hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer
administration, oral
evaluation of the transparency committee
breast neoplasms
palbociclib

---
https://www.has-sante.fr/jcms/p_3447978/fr/ibrance-palbociclib-cancer-du-sein
2023
false
false
false
France
administration, oral
insurance, health, reimbursement
treatment outcome
tablets
Product containing only palbociclib in oral dose form (medicinal product form)
hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer
postmenopause
antineoplastic agents
evaluation of the transparency committee
palbociclib
breast neoplasms

---
https://www.e-cancer.fr/content/download/443877/6711331/file/MEP_INCA_RecoInhibiteursCDK4_6_vdef.pdf
2022
France
practice guideline
ribociclib
abemaciclib
ribociclib
palbociclib
palbociclib
abemaciclib

---
https://www.has-sante.fr/jcms/c_2964747/fr/ibrance
2019
false
false
false
France
treatment outcome
palbociclib
antineoplastic agents
protein kinase inhibitors
palbociclib
antineoplastic combined chemotherapy protocols
Letrozole
postmenopause
breast neoplasms
Fulvestrant
Hormone receptor positive malignant neoplasm of breast (disorder)
administration, oral
evaluation of the transparency committee
piperazines
pyridines

---
https://www.has-sante.fr/portail/jcms/c_2964747/fr/ibrance
2019
false
false
false
France
French
palbociclib
antineoplastic agents
protein kinase inhibitors
breast neoplasms
neoplasm metastasis
Locally Advanced Malignant Neoplasm
antineoplastic combined chemotherapy protocols
Hormone receptor positive malignant neoplasm of breast (disorder)
administration, oral
Cyclin-Dependent kinase 4
Cyclin-Dependent kinase 6
survival analysis
Progression-Free survival
Human epidermal growth factor 2 negative carcinoma of breast (disorder)
treatment outcome
evaluation of the transparency committee
postmenopause
Stage IV Breast Cancer AJCC v6 and v7
Locally advanced breast cancer
HER2/Neu Negative
palbociclib
piperazines
pyridines
disease-free survival
Progression-Free Survival

---
https://www.has-sante.fr/jcms/c_2964747/fr/ibrance-palbociclib-inhibiteur-de-proteine-kinase
2019
false
false
false
France
guidelines for drug use
protein kinase inhibitors
palbociclib
antineoplastic combined chemotherapy protocols
Letrozole
breast neoplasms
Hormone receptor positive malignant neoplasm of breast (disorder)
Human epidermal growth factor 2 negative carcinoma of breast (disorder)
administration, oral
postmenopause
evaluation of the transparency committee
palbociclib
piperazines
pyridines
piperazines
pyridines

---
https://www.has-sante.fr/portail/jcms/c_2761877/fr/ibrance
2017
false
false
false
France
French
palbociclib
antineoplastic agents
protein kinase inhibitors
breast neoplasms
neoplasm metastasis
Locally Advanced Malignant Neoplasm
antineoplastic combined chemotherapy protocols
Hormone receptor positive malignant neoplasm of breast (disorder)
administration, oral
Cyclin-Dependent kinase 4
Cyclin-Dependent kinase 6
survival analysis
Progression-Free survival
Human epidermal growth factor 2 negative carcinoma of breast (disorder)
treatment outcome
evaluation of the transparency committee
postmenopause
Stage IV Breast Cancer AJCC v6 and v7
Locally advanced breast cancer
HER2/Neu Negative
palbociclib
piperazines
pyridines
disease-free survival

---
https://www.ema.europa.eu/medicines/human/EPAR/Ibrance
2016
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
palbociclib
palbociclib
drug approval
europe
antineoplastic agents
antineoplastic agents
protein kinase inhibitors
protein kinase inhibitors
breast neoplasms
neoplasm metastasis
Locally Advanced Malignant Neoplasm
antineoplastic combined chemotherapy protocols
Hormone receptor positive malignant neoplasm of breast (disorder)
administration, oral
Cyclin-Dependent kinase 4
Cyclin-Dependent kinase 6
survival analysis
Progression-Free survival
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
Human epidermal growth factor 2 negative carcinoma of breast (disorder)
palbociclib
piperazines
pyridines
disease-free survival
piperazines
pyridines

---
Nous contacter.
17/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.